Hyperglycemia impairs nerve fibers of dorsal root ganglia (DRG) neurons, leading to diabetic peripheral neuropathy (DPN). However, the molecular mechanisms underlying DPN are not fully understood. Using a mouse model of type II diabetes (db/db mouse), we found that microRNA-34a (miR-34a) was over-expressed in DRG, sciatic nerve, and foot pad tissues of db/db mice. In vitro, high glucose significantly upregulated miR-34a in postnatal and adult DRG neurons, which was associated with inhibition of axonal growth. Overexpression and attenuation of miR-34a in postnatal and adult DRG neurons suppressed and promoted, respectively, axonal growth. Bioinformatic analysis suggested that miR-34a putatively targets forkhead box protein P2 (FOXP2) and vesicle amine transport 1 (VAT1), which were decreased in diabetic tissues and in cultured DRG neurons under high glucose conditions. Dual-luciferase assay showed that miR-34a downregulated FOXP2 and VAT1 expression by targeting their 3′ UTR. Gain-of-and loss-of-function analysis showed an inverse relation between augmentation of miR-34a and reduction of FOXP2 and VAT1 proteins in postnatal and adult DRG neurons. Knockdown of FOXP2 and VAT1 reduced axonal growth. Together, these findings suggest that miR-34a and its target genes of FOXP2 and VAT1 are involved in DRG neuron damage under hyperglycemia.
Introduction
Hyperglycemia induces axonal damage of dorsal root ganglia (DRG) neurons, leading to diabetic peripheral neuropathy (DPN) [1, 2] . Molecular mechanisms underlying distal axonal loss in DPN are not fully understood. Multiple mechanisms including polyol pathway, hexosamine and protein kinase C (PKC), advanced glycation end products, free fatty acids, ion conductance, mitochondrial dysfunction, insulin resistance and inflammation, have been well demonstrated preclinically in mediating the development of DPN [1] [2] [3] . However, clinical trials targeting these mechanisms have failed [1] . Increasing evidence shows that microRNAs (miRNAs), for example, miR-338, miR-16, miR181d, miR-132, miR-9, miR-17-92, and miR-29c, play critical roles in regulating axonal development [4] . In addition, miRNAs are involved in diabetes and diabetes-induced complications [5] . Mice with diabetic neuropathic pain exhibit reduction of miR-184 and miR-190a in spinal cord tissue [6] , while diabetic rats showed downregulation of miR-29b in DRG neurons [7] . Moreover, miR-7a regulates excitability of DRG neurons in a neuropathic pain model [8] , whereas miR-21 and miR-222 inhibit apoptosis of DRG neurons induced by sciatic nerve injured [9] . Although miR34a has been well demonstrated to regulate cancer cell growth [10] , recent studies show that patients with diabetes have high serum levels of miR-34a [11] . Experimental studies show that an increased miR-34a in islets is associated with the progression of the diabetes, and that fatty acids upregulate miR-34a expression in pancreatic β-cells [12, 13] . These data suggest that miR-34a may be involved in diabetic metabolic dysfunction. Moreover, miR-34a has been shown to regulate neurite outgrowth, spinal morphology and function [14] . However, the role of miR-34a in DPN remains unknown.
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Here, using a mouse model of type II diabetes (db/db mice) and cultured DRG neurons, we report that hyperglycemia increases miR-34a in DRG neurons and suppresses axonal growth through regulating genes of FOXP2 and VAT1. FOXP2 is a transcription repressor and regulates neurite growth during nervous system evolution [15] . VAT1 is a membrane protein of cholinergic synaptic vesicles [16] . The role of these two genes in DPN is not known. Our data for the first time suggest that miR-34a and its target genes FOXP2 and VAT1 are involved in DPN.
Research Design and Methods
All experimental procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Henry Ford Hospital.
Isolation of DRG, Sciatic Nerve and Foot Pad Tissues
DRG, sciatic nerve (SN) and foot pad (FP) tissues were harvested from BKS.Cg-m +/+ Lepr db /J (db/db) mice (Jackson Laboratories, Bar Harbor, ME, USA) at the age of 20 weeks when mice exhibited peripheral neuropathy [17] (Fig s1) . The db/db mouse has a point mutation in the leptin receptor gene causing severe depletion of the insulin-producing beta-cells of the pancreatic islets, hyperglycemia and eventually leading to diabetes [18] . The age-matched heterozygote mice (db/m) were used as control. Physiological parameters of db/m and db/db mice including blood glucose levels were measured (Fig s1) .
Culture of Primary Postnatal and Adult DRG Neurons
DRG neurons were harvested from newborn C57L/J mice (Jackson Laboratories) at postnatal day 0-1 or adult (20 weeks) db/m and db/db mice and were cultured according to published protocols [19, 20] . Briefly, the DRGs were collected and then transferred into neurobasal medium (Invitrogen, Carlsbad, CA, USA) containing 0.25% trypsin (Thermo Fisher Scientific, Waltham, MA, USA) digestion at 37°C for 30 min. DRG neurons were mechanically triturated with a Pasteur pipette for 15 times and then the cells were passed through a 70-μm cell strainer (Fisher Scientific, Hampton, NH, USA) and counted to obtain a concentration of 1 × 10 7 cells/ml. Postnatal DRG neurons were cultured in a microfluidic chamber (Xona Microfluidics, Temecula, CA, USA). Microgrooves embedded in the chamber allow only axons to pass and reach the axonal compartment [20, 21] . Sterilized chambers were affixed to poly-D-lysine-coated (SigmaAldrich, St. Louis, MO, USA) dishes (35 mm, Corning, Corning, NY). Postnatal DRG neurons were cultured at a density of 1 × 10 6 cells/chamber, and adult DRG neurons were cultured at a density of 1 × 10 5 in DMEM (Thermo Fisher Scientific) with 5% FBS (Corning) for 4 h. Then the medium was replaced with neurobasal medium (Invitrogen), 50 ng/ml nerve growth factor (NGF) (Sigma-Aldrich), 2% B-27 (Invitrogen), 2 mM GlutaMax (Thermo Fisher Scientific), and 1% antibiotic-antimycotic (Thermo Fisher Scientific). The 5-fluorodeoxyuridine (Abcam, Cambridge, UK) was added to purify the neurons. The medium was changed with non-5-fluorodeoxyuridine neurobasal medium on day in vitro (DIV) 3. Then, the medium was replaced every other day. Additional 5 mM glucose was added into the neurobasal medium containing 25 mM glucose to reach a final concentration of 30 mM glucose that has been shown to be the optimal condition for culturing DRG neurons [22] . To induce a high glucose (HG) condition, additional 30 mM glucose was applied into the neurobasal medium. In the present study, we thus termed 30 and 55 mM glucose media as regular glucose (RG) and HG, respectively.
Transfection of DRG Neurons
Postnatal and adult DRG neurons were transfected with miR-34a mimics, miR-34a hairpin inhibitors, and their corresponding controls (Dharmacon, Lafayette, CO, USA) using Nucleofector™ kit (Lonza, Basel, Switzerland). Briefly, 200 pmol/well of miRNA mimics and inhibitors were mixed with 100 μl of Nucleofector solution (Lonza). Then, DRG neurons with the transfection solution were transferred into a cuvette. The program O-03 was used for electroporation [23] . SiRNAs against FOXP2 and VAT1, or controls (0.1 μM, Santa Cruz, Santa Cruz, CA, USA) were transfected using the same protocol.
Isolation of Total RNA and Real-Time RT-PCR Analysis
MiRNeasy Mini kit (Qiagen, Hilden, Germany) was used to isolate total RNA from cultured DRG neurons (DIV6), or tissues of DRGs, sciatic nerves and foot pads of db/db and db/m mice. Quantitative RT-PCR (qRT-PCR) analysis was performed on ABI 7000 and ABI ViiA 7 PCR instrument (Applied Biosystems, Foster City, CA, USA) according to published methods [24, 25] . The following miRNA primers w e r e u s e d : m i R -3 4 a ( m a t u r e s e q u e n c e : UGUUGGUCGAUUCUGUGACGGU) and U6 snRNA T was used to calculate the relative levels [26] .
Dual-Luciferase Assay
Dual-Luciferase assay was performed according to our published protocol [27] . Briefly, the segments of the 3′ UTR of FOXP2 (MmiT037037, Genecopoeia, Rockville, MD, USA) and VAT1 (MmiT030775, Genecopoeia) gene encompassing the miR-34a binding site were cloned into a pEZX-MT06 vector with Firefly/Renilla duo Luciferase reporter driven by a CMV promoter (Genecopoeia) (Fig. 6b) . Mutations of 3′ UTR in miR- 34a binding site of FOXP2 (ACTGCCA to TACCAGC) and VAT1 (CACTGCCA to GCCACACT) gene were made, and confirmed by sequencing (Fig. 6b) . Wild-type or mutant vectors were transfected into HEK293 cells by lipofectamine (Life technologies, Carlsbad, CA, USA) at a concentration of 2 μg/106 cells. To test the interaction between miR-34a and 3′ UTR of FOXP2 or VAT1 gene, each vector was co-transfected with miR34a mimics (200pM/10 6 cells, Dharmacon). Twenty-four hours later, HEK293 cells were lysed and treated with a Dualluciferase assay kit (Genecopoeia). Luciferase activity was measured by multimode microplate reader (PerkinElmer/Fusion).
Western Blot Analysis
Total proteins from cultured DRG neurons were isolated on DIV6 according to published protocols [25, 27] . Total protein from DRG, sciatic nerve and foot pad tissues of db/db and db/ m mice were extracted using the same methods. In vitro samples from 4 individual microfluidic chambers were pooled for one Western blot. The protein concentration was measured using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Western blot was performed according to previously described methods [25, 27] . Briefly, equal amounts of proteins were loaded. Primary antibodies were rabbit anti-ADAM10 (a disintegrin and metalloproteinase domaincontaining protein 10, 1:1000, Abcam, Cambridge, UK), rabbit anti-DCX (doublecortin, 1:500, Abcam), rabbit anti-c-MET (tyrosine-protein kinase met, 1:500, Abcam), rabbit anti-FOXP2 (1:1000, Abcam), goat anti-NOTCH1 (1:1000, Santa Cruz), rabbit anti-ROCK1 (Rho associated coiled-coil containing protein kinase 1, 1:500, Abcam), rabbit anti-SYNJ1 (Synaptojanin 1, 1:1000, Sigma-Aldrich), rabbit 
Immunofluorescent Staining and Axonal Measurement
Axonal staining and measurement were performed as previously described [20, 23] . Briefly, monoclonal antibodies against phosphorylated neurofilament heavy protein (SMI31, 1:1000, Covance, Battle Creek, MI, USA) or class III beta-tubulin (TUJ1, 1:1000, Biolegend, San Diego, CA, USA) were used. For postnatal DRG neurons, the lengths of the 15 longest axons in each chamber were measured using a microscopic computer imaging device (MCID) system. The axonal length was recorded for 3 days from DIV3 to DIV5. For adult DRG neurons, one time point axonal length was measured on DIV3 according to a published protocol [28] . Immunostaining for DRG tissues was performed according to a published protocol [24] . Briefly, L3-L6 DRGs were isolated, fixed in 4% paraformaldehyde, and embedded in paraffin. The slices were cut in 6 μm thickness. The following primary antibodies were used: rabbit anti-FOXP2 (1:50, Abcam) and goat anti-VAT1 (1:50, Santa Cruz). Cellular nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (1:10000, Thermo Fisher Scientific). A polyclonal antibody against protein gene product 9.5 (PGP 9.5, 1:1000; Millipore) was used to detect intraepidermal nerve fibers in plantar skin. The nerve fiber densities were calculated according to a published protocol [29] .
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) in combination with fluorescent immunostaining were performed according to a published protocol [30] . Briefly, the cells were fixed in 4% paraformaldehyde, and then hybridized with a miR-34a LNA (locked nucleic acid) probe, and the probe was detected with peroxidase-conjugated anti-FAM (Roche, Basel, Switzerland) followed by incubation tyramine-signal-amplification (TSA)-Cy3 substrate for 10 min at room temperature. Fluorescent immunostaining was then performed with primary antibodies against TUJ1 (a marker of neuroblasts) and FITC-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA).
Bioinformatic Analysis
Bioinformatics were analyzed using TargetScan [31] , Ingenuity Pathways Analysis (IPA) and string-db.org. For IPA, Fischer's exact test was used to calculate the P value.
Statistical Analysis
Data were analyzed by using SPSS 11.5. One-way ANOVA with post hoc Bonferroni tests was used for multiple group experiment analysis. Student's test was used for two group comparisons. A value of P < 0.05 was considered as significant. Values are presented as mean ± standard deviation (SD).
Results

MiR-34a Is Increased in Diabetes and Regulates Axonal Growth
To examine whether diabetes affects miR-34a expression, we measured miR-34a levels in DRG, sciatic nerve and foot pad tissues by means of qRT-PCR. Our data showed that miR-34a levels were significantly (p < 0.05) increased in DRG (1.9 ± 0.2 vs 1.0 ± 0.1, mean ± SD, n = 6), sciatic nerve (2.1 ± 0.3 vs 1.0 ± 0.2, n = 6) and foot pad (1.9 ± 0.2 vs 1.1 ± 0.2, n = 6) tissues of diabetic db/db mice at age of 20 weeks compared to those of age-matched non-diabetic db/m mice (Fig. 1a) .
In vitro experiments showed that miR-34a levels were also increased in postnatal (2 ± 0.3 vs 1.0 ± 0.1, n = 6, P < 0.05) and adult DRG neurons (2.8 ± 0.4 vs 1.0 ± 0.1, n = 6, P < 0.05) under HG conditions (Fig. 1b) . In situ hybridization further confirmed that miR-34a increased in DRG neurons under HG conditions (Fig. 2a, b) . We then assessed the role of miR-34a in axonal growth by transfecting postnatal DRG neurons with miR-34a inhibitors or mimics under HG conditions ( Fig. 1c-d) . The efficacy of transfection was confirmed Fig. 3 Reduction of FOXP2 and VAT1 proteins in diabetic mouse tissues. a-c Representative Western blots show protein levels of FOXP2 and VAT1 in DRG (a), sciatic nerve (SN, b) and foot pad (FP, c) tissues of db/db or db/m mice. Three individual mice were presented for each group and β-actin was used as an internal loading control. d, e Quantitative data show levels of FOXP2 (d) and VAT1 (e) in DRG, SN and FP. n = 6 mice/group. *P < 0.05 vs db/m mice by qRT-PCR analysis showing that miR-34a inhibitors and mimics reduced and increased, respectively, miR-34a levels in DRG neurons (Fig. 1b) . To examine the effect of alteration of miR-34a levels on axonal growth, transfected postnatal DRG neurons were cultured in the microfluidic device and distal axonal length within the axonal compartment was measured. Our pilot experiments demonstrated that axons of postnatal and adult DRG neurons were SMI31 and TUJ1 immunoreactive, and double immunofluorescent staining showed co-localization of SMI31 and TUJ1 (Fig. s2) , which is consistent with data from others [32] . Thus, SMI31 or TUJ1 positive axons were used for measurements of axonal length. As we expected, HG substantially reduced axonal length by 22% on DIV 5 compared to RG (Fig. 1c, d) . However, miR-34a inhibitors completely suppressed HG-reduced axonal length, whereas miR-34a mimics further significantly (p < 0.05) decreased HG-reduced axonal length (Fig. 1c, d) . To examine the effect of miR-34a on adult DRG neurons, transfected DRG neurons were cultured in regular dishes due to technical challenges to culture adult DRG neurons in the microfluidic device. In line with the data from postnatal DRG neurons, HG reduced axonal length by 58%, which was completely suppressed by miR-34a inhibitors and was further substantially (p < 0.05) decreased by miR-34a mimics (Fig. 1e, f) . These data suggest that miR-34a regulates axonal growth of postnatal and adult DRG neurons.
FOXP2 and VAT1 Are Involved in MiR-34a-Mediated Axon Growth under Hyperglycemia Condition
In our preliminary studies, we examined protein levels of ADAM10, DCX, c-MET, NOTCH1 and ROCK1 genes putatively targeted by miR-34a, based on bioinformatic analysis. These genes are highly involved in pathways that are related to development of neurons, neuritogenesis, and branching and growth of neurites ( Fig. s3a-d) . However, Western blot analysis showed that none of these protein levels were altered in DRG, SN and FP tissues of db/db mice compared to db/dm mice ( Fig. s4a-j) . Thus, we searched other miR-34a putative target genes associated with the nervous system and found SMAD4, FOXP2, SYNJ1, VAMP2 and VAT1 genes. Among them, we detected reduction of FOXP2 and VAT1 proteins in diabetic mice (Fig. 3a-e) . Thus, we focused on these two genes. Western blot analysis of DRG, SN and FP tissues from db/db and db/m mice showed that FOXP2 and VAT1 protein levels were significantly reduced in DRG by 48% and 45%, respectively, SN by 38% and 48%, respectively, and FP 45% and 42%, respectively, tissues of db/db mice compared to protein levels in db/m mice (Fig. 3a-e) .
Moreover, compared to RG conditions, HG significantly (p < 0.05) reduced FOXP2 and VAT1 proteins in cultured postnatal and adult DRG neurons (Fig. 4a, b ). An inverse relation between augmentation of miR-34a and reduction of FOXP2 and VAT1 proteins suggests that miR-34a could target these two genes in DRG neurons. We thus performed in vitro experiments to assay the direct effect of miR-34a on FOXP2 and VAT1 genes using a dual-luciferase reporter approach, in which HEK293 cells were transfected by a plasmid containing miR-34a binding site at 3'UTR of FOXP2 and VAT1 genes (Fig. 4c) . The luminescence analysis showed that miR-34a mimics significantly (p < 0.05) reduced luminescence activity of FOXP2 or VAT1 vector by 62% or 70%, respectively (Fig.  4d-e) . In contrast, miR-34a mimics did not reduce luminescence activities when miR-34a seed sequences at 3' UTR of FOXP2 or VAT1 were mutated (Fig. 4d-e) . Furthermore, transfection of postnatal and adult DRG neurons with miR -34a mimics or inhibitors resulted in decreases or increases, respectively, of FOXP2 and VAT1 protein levels in DRG neurons (Fig. 4f-h ). Collectively, these data indicate that miR-34a regulates expression of FOXP2 and VAT1 by targeting their 3'UTR.
To examine whether FOXP2 and VAT1 regulate axonal growth, we transfected postnatal and adult DRG neurons with siRNAs against FOXP2 or VAT1 and then cultured transfected DRG neurons under RG conditions. Western blot analysis showed that siRNAs against FOXP2 or VAT1 significantly (p < 0.05) reduced FOXP2 or VAT1 levels in DRG neurons (Fig. 5a,b and Fig. 6a,b) . Knockdown of endogenous FOXP2 or VAT1 robustly (p < 0.05) reduced axonal growth by 23% and 20% in postnatal neurons, or by 29% and 26% in adult neurons, respectively, compared to the controls (Fig. 5c-f and Fig. 6c-f) , suggesting that FOXP2 and VAT contribute to axonal growth of DRG neurons.
Discussion
We have demonstrated that miR-29c mediates axonal growth of DRG neurons under hyperglycemia via targeting a gene that encodes a member of the protein kinase C (PKC) iota, PRKCI [33] . Here, we show that hyperglycemia upregulates miR-34a in DRG neurons. Importantly, we show that an increased miR-34a suppresses axonal growth by targeting FOXP2 and VAT1 genes. Together, these findings suggest that miRNAs mediate diabetes-induced axonal damage of DRG neurons. Degeneration of distal sensory axons of DRG neurons is the major cause of DPN [1] . Although DPN has been intensively studied, molecular mechanisms underlying distal axonal damage have not been fully explored [1, 2] . Emerging experimental and human data suggest that miRNAs are involved in DPN [34] . Patients with T2D exhibit neuropathy susceptibility when they have polymorphisms in miRNA genes such as miR-146a [35] . A recent study in type I diabetic mice shows that DPN significantly alters miRNA profiles including miR-34a in DRG neurons, and that administration of exogenous let-7i miRNA substantially ameliorates DPN by marked augmentation of epidermal nerve fibers [36] . We previously demonstrated that miR-29c is a negative regulator of axonal growth of DRG neurons by targeting PRKCI under hyperglycemia [33] . The present study shows that attenuation and elevation of miR-34a in DRG neurons promotes and inhibits, respectively, axonal growth under HG condition, providing new evidence that miR-34a mediates axonal growth of sensory neurons. Alteration of miR-34a levels has been associated to diabetes. For example, patients with diabetes have elevated serum levels of miR-34a, while increased miR-34a has been detected in [11] blood, liver and pancreas of diabetic animals [34] . Moreover, miR-34a regulates neurite outgrowth and spinal morphology and function [14] .
FOXP2 and VAT1 are genes putatively targeted by miR34a based on Targetscan and studies in cancer [37] . We for the first time demonstrated that miR-34a targets a seed region in 3' UTR of FOXP2 and VAT1 genes and that downregulation of FOXP2 and VAT1 reduces axonal growth. These findings underscore new function of miR-34a/FXOP2/VAT1 in mediating DPN.
FOXP2 was the first gene found to cause speech and language disorders and autism spectrum disorder [38] . Later studies demonstrated that FOXP2 protein, as a transcription factor, plays important roles in regulating development of the CNS [15] . For example, Groszer et al. reported that a mutation of FOXP2 leads to abnormal synaptic plasticity in mice [39] , while Horng et al. demonstrated that Foxp2 protein is required for synaptic plasticity of the auditory pathway [40] . Others showed that FOXP2 regulates a series of gene networks that are involved in neurite outgrowth in the developing brain [41] . Moreover, a recent study showed that FOXP2 is necessary for glucose metabolism in mediating islet alpha cell proliferation and function [42] , suggesting that FOXP2 may have a role in diabetes. The present study shows that FOXP2 in DRG neurons regulated axonal growth. Specifically, we found that hyperglycemia down-regulated FOXP2 and attenuation of endogenous FOXP2 resulted in reduction of axonal growth. Thus, in addition to the CNS, FOXP2 regulates peripheral sensory neuron function.
VAT1 was originally described in torpedo fish as an integral membrane protein that plays a central role in the function of synaptic vesicles [16] . Subsequent studies showed that VAT1 is involved in dopamine biosynthesis and synaptic release [43] . The presynaptic release apparatus is highly mobile in axons [44] and axonal transporters of synaptic vesicles mediate autonomic neuropathy [45] , suggesting that VAT1 as a synaptic vesicle membrane protein has a role in axonal growth. Moreover, VAT1 possesses ATPase activity [46] that is highly involved in diabetes and diabetic neuropathy [47, 48] . Our findings showed that hyperglycemia downregulated VAT1 expression in DRG neurons, while loss of VAT1 in DRG neurons decreased axonal growth. These findings are in parallel with a role of VAT1 in mediating synaptic function [45] [46] [47] [48] . Thus, VAT1 could play a role in DPN.
Collectively, our in vitro and in vivo data for the first time demonstrate that miR-34a mediates axonal growth of DRG neurons by targeting FOXP2 and VAT1 genes under hyperglycemia. However, additional in vivo studies are warranted to investigate whether miR-34a locally regulates FOXP2 and VAT1 protein levels in the distal axons of diabetic mice, as DPN commonly initially damages distal sensory nerve fibers [49] .
